The initiative centers on Nona’s proprietary Harbour Mice platform, which produces fully human heavy chain-only antibodies. By integrating this technology with Lonza’s GS Gene Expression System and GlycoConnect bioconjugation expertise, the companies intend to optimize candidates for clinical use. The agreement includes upfront payments to Nona and a revenue-sharing model for future licensing deals.
In section Releases
Nona Biosciences and Lonza Partner to Crack the Blood-Brain Barrier
Nona Biosciences and Lonza have launched a strategic collaboration to engineer single-domain antibody technology capable of crossing the blood-brain barrier. The partnership aims to facilitate the delivery of therapeutic agents directly into the central nervous system, addressing a significant hurdle in the treatment of complex neurological disorders.
Dr. Jingsong Wang, Chairman of Nona Biosciences, noted that Lonza’s manufacturing and regulatory infrastructure will be critical in accelerating the advancement of these delivery technologies. Lonza’s Head of Licensing, Peter Droc, emphasized that the acquisition of rights to this technology allows the firm to provide clients with a streamlined path for translating CNS drug candidates into viable therapies. This integration of discovery and manufacturing seeks to reduce the development complexity typically associated with CNS-targeted medicine.
Comments (0)
No comments yet. Be the first!